Conducted in 74 hospitals throughout the United Kingdom, TNT (NCT00532727) was a phase III, parallel group, open-label randomised controlled trial with preplanned biomarker subgroup analyses. The results are published on 30 April 2018 in the Nature Medicine. The authors wrote that the PARP inhibitor olaparib is now approved in advanced germline-mutated BRCA1/2 breast cancer, but this treatment may remain